sufficient dose of islets to achieve insulin independence are yet to be seen. On this last point, while large capsules help to curtail fibrosis, their use also dramatically increases the volume of the islet graft. The large capsules are 10 times larger in diameter and 1,000 times larger in volume than islets, which have an average diameter of 150 μm. Islets from one donor normally will have a pack volume of 2-5 ml. If islets are singly encapsulated in the large spheres, the graft volume will balloon to 2-5 l, reaching the limit of what the peritoneal cavity can accommodate. Packing more islets into a single capsule can reduce the graft volume, but the viability of the islets crowded into the capsules will need to be readdressed.
Progress in encapsulated cell therapy is moving forward rapidly. This work shows us the importance of optimizing not only the capsule material and size, but also the animal model and transplant site. The knowledge gained will be important for not just islet encapsulation but also the use of these approaches for immune isolation of β-cells from novel sources such as stem cells and genetically modified pigs, and potentially other cell-based therapies. www.nature.com/nrendo N e w s & V i e w s Type 2 diabetes mellitus (T2DM) is a cardiometabolic disorder, the pathognomonic characteristic of which is hyperglycaemia 1 . The diagnosis of T2DM is, in fact, based on the measurement of glycaemia, either during a fasting state or 2 hours after a challenge of oral glucose, or on the assessment of levels of HbA 1c , a parameter that is also used by clinicians to monitor glucose control as it is indicative of the mean glucose levels during the preceding 3 months.
The three criteria, however, are not always concordant as some patients could be diagnosed with T2DM according to one (for example, after glucose challenge) but not another (such as measuring levels of HbA 1c ) criterium 2 . This simple observation suggests both the inappropriateness of using thresholds and categorizing patients into different ranges of levels of glucose or HbA 1c and, at the same time, the oversimplification of a single condition defined as 'type 2 diabetes mellitus' despite the underlying presence of heterogeneous glucose dysregulation 3 . Such heterogeneity probably reflects the different contributions of multiple pathophysiological pathways (for example, peripheral insulin resistance and β-cell failure) leading to hyperglycaemia; moreover, in epidemiological studies, different phenotypes of T2DM have also been associated with a heterogeneous risk of complications, mainly cardiovascular diseases 4 . Over the past decade, the possibility to monitor levels of glucose for several days with continuous rather than discrete, spotted measurements has substantially expanded our knowledge about glucose regulation and has given further insights into its hetero geneity.
Examining glucose profiles has shown that excursions of glucose levels could differ among individuals with the same mean glucose level, a condition that was expected from a theoretical point of view and confirmed experimentally using continuous monitoring 5 .
As a corollary argument, it was speculated that the glucose excursions could be a risk factor for complications related to diabetes mellitus independent of mean glucose control (that is, HbA 1c ). Such a hypothesis, popularized as 'glycaemic variability' , represented a paradigm shift in the management of hyperglycaemia in diabetes mellitus, whereby health-care professionals should not only focus on controlling mean levels of glucose (HbA 1c ), but also on glycaemic variability to reduce the risk of vascular complications. Extensive preclinical and clinical evidence further confirmed the importance of glucose variability 5 ; however, to date there has been no definite evidence from clinical trials of a causative role for glycaemic variability on the risk of complications related to diabetes mellitus.
The recent report by Heather Hall and colleagues 6 has further shed light upon the heterogeneity of glucose regulations. In this study, using analytical methods to detail glucose excursions from continuous glucose monitoring (CGM) over several days, the glucose profiles of 57 healthy participants without a known diagnosis of T2DM were investigated. The authors classified participants according to the pattern of glucose variations as low, moderate and severe variability 'glucotypes' . Subsequently, the characteristics (such as age and BMI) of the patients, their metabolic profiles (fasting 
Glucose dysregulation phenotypes -time to improve outcomes

Francesco Zaccardi and Kamlesh Khunti
Detailed profiles of fluctuations in glucose obtained via continuous glucose monitoring highlight the complexity of glucose regulation and underscore that the definition of type 2 diabetes mellitus as a homogeneous disease is an oversimplistic approximation for a heterogeneous metabolic disorder. Whether better phenotyping would ultimately result in improved interventions and outcomes, however, remains largely unproven.
Refers to Hall, H. et al. Glucotypes reveal new patterns of glucose dysregulation. PLOS Biol. 16, e2005143 (2018).
volume 14 | NovemBeR 2018 | 633 NatuRe Reviews | Endocrinology N e w s & V i e w s long-term patient outcomes compared with the one-size-fits-all model 9, 10 . The pathophysiological study by Hall and colleagues 6 represents a further step in understanding the complexity of glucose regulation and dysglycaemia in T2DM. However, as frequently mentioned by the authors in their article, the potential clinical implications of the results need to be ascertained. We agree and hope that their detailed investigation will not remain only an initial step in personalized medicine research, similar to other previous pathophysiological studies. The accumulating evidence of the heterogeneity of T2DM is now robust; the lack of further prognostic research and of randomized clinical trials exploring the implication of personalized interventions suggests that researchers, institutions and public and private funders are missing the opportunity to potentially translate robust experimental results into better outcomes for patients with T2DM. and post-challenge levels of glucose, peripheral insulin resistance, insulin secretion and glucose excursions following standardized meals) and cross-comparisons with established criteria of T2DM were compared across the three glucotypes.
From a large set of almost 500,000 measurements, there are several main findings. First, some participants categorized as having no T2DM according to current diagnostic criteria have, on the contrary, glucose levels over the diagnostic thresholds for pre-diabetes or T2DM during CGM (particularly in individuals with severe glucose variability). Second, glucose excursions following a meal depend on the qualitative food composition (similar calories but varying amounts of protein, fat, carbohydrate and fibre) and for the same food the glucose excursions are different among participants. Third, insulin secretion, insulin resistance and fasting and post-challenge levels of glucose correlated with glucotypes.
The pathophysiological and potential clinical implications of this study are immediately clear. First, glucose dysregulation is far more heterogeneous than expected and the utility of a single threshold to rigidly categorize patients in a disease status is far from being correct and physiologically unjustified. Second, the assumption of similar glucose excursions for the same amount and composition of food, which is frequently used in clinical practice to adjust insulin dose, has been disproved in this study. Third, glucose profiles depend on the heterogeneous interplay between pathophysiological determinants of insulin resistance (liver and muscle) and insulin secretion (β-cell and the incretin effect). Last, a wider use of CGM could help identify a very early stage of glucose dysregulation in apparently 'healthy' individuals with the possibility of very early intervention potentially resulting in better long-term outcomes. As the evidence from randomized clinical trials of reducing the risk of cardiovascular outcomes and mortality following early intervention in screen-detected diabetes mellitus and pre-diabetes is discordant 7, 8 , the phenotypes defined with the author's algorithm could result in a greater predictive value and potentially better patient outcomes. However, the widespread use of CGM should be carefully considered regarding the balance between its cost and effectiveness.
Biomedical research involved in identifying phenotypes of diseases has been extensively funded and represents one of the rising research fields of the past decade. Fuelled principally by the advancements in genetics, efforts to describe different phenotypes for medical conditions that are considered unique nosological entities are common in cancer, cardiovascular diseases and diabetes mellitus medicine. The aim of such studies is to stratify the prognosis and tailor treatments, an approach commonly referred to as personalized or precision medicine. Although guidelines on precision medicine have been published to facilitate and guide researchers in translating initial observations into clinically relevant results, most of the initial promises have remained confined to early preclinical or clinical studies with unproven translated benefit for patients. As a result, for both T2DM and most other medical conditions there is very limited evidence that a model of a personalized treatment approach based on detailed phenotyping would result in better wider use of CGM could help identify a very early stage of glucose dysregulation
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